Diabetes 콜백앱 and sore feet? Unfortunately, this is not uncommon. Diabetes is a chronic disease that affect kidneys, eyes, feet and heart. The increased blood sugar level disturbs the sensitive nerves and causes disturbances in the large and small blood vessels. Disruption of the small blood vessels, in particular, is a major factor that develops a diabetic foot. It has been estimated that over 50% of lower extremity amputations are linked to diabetes. India has the largest number of diabetics in the world.

The healthcare costs and 콜백앱 loss of productivity associated with diabetic foot complications are enormous and all efforts are needed to prevent this. Footwear which are either inappropriate or not used enough, or a lack of footwear are the most common causes of trauma resulting in foot ulcers. The diabetic foot ulcers can be prevented by regular foot inspection, foot-care and wearing appropriate footwear.

The research on suitability of footwear in Indian conditions prompted CSIR-Central Leather Research Institute (CLRI) to collaborate with M/s MV Diabetes Hospital and Diabetes Research Centre, 콜백앱 Chennai, in developing a special footwear, called DIASTEP, to reduce diabetic foot complications and ensure a better quality of life.

DIASTEP is a therapeutic open footwear for diabetic patients that reduces the abnormal distribution of plantar foot pressure. Patients with diabetic foot risk, are provided with a complete open footwear, comprising selective topsole, insole and bottom sole made of appropriately selected material. The therapeutic footwear has a cow softy upper leather, a unit moulded sole made from PolyUrethane (PU) with extra depth to provide larger area 콜백앱 for more effective pressure distribution and outsole having special tread for better grip and traction. The designed footwear has established their efficacy with extensive patient trials in which a careful selection of patients was made and an adjusted sandal was fabricated. The footwear was fabricated with specially derived Rocker bottomed soles, to relieve biomechanical stresses and was tested for its pressure reduction. The efficacy of the developed footwear was examined for reducing shock, preventing foot debilitation whilst additionally providing comfort to the wearer and also 콜백앱 prevent the foot complication from progressing to the next higher level of risk.

DIASTEP was patented on 30th October 2018 (Patent no 302551). The footwear making technology has being transferred to M/s M V Health Care Pvt. Ltd.

Dr Vijay Viswanathan, Head & Chief Diabetologist
(M.V. Hospital for Diabetes & Prof M Viswanathan Diabetes Research Centre);


Dr K J Sreeram (Director, CSIR-CLRI)
Dr T Ramasami (Former Director, CSIR-CLRI)
Prof Dr A B Mandal (Former Director, CSIR-CLRI)
Dr B N Das, Dr Gautham G, Mr Md Sadiq, Dr D Suresh Kumar (CSIR- 콜백앱 CLRI).